close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

121.71 -0.81 (-0.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
22 23 Next >
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money
There's no guarantee of 100% returns for these stocks, but their chances look pretty good. 
Via The Motley Fool
12 Top Stocks to Buy in December
Add this dandy dozen to your stocking this month. 
Via The Motley Fool
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
The S&P 500 is fighting for its 200-day, a critical level for the uptrend. 
Via Investor's Business Daily
Axsome Therapeutics Stock: Bear vs. Bull
2023 will almost certainly see Axsome's top line explode higher. 
Via The Motley Fool
Axsome Therapeutics's Return On Capital Employed Insights
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Struggling Axsome Stock Could Bounce Back on Drug Trial Success
Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that. 
Via MarketBeat
Analyst Ratings for Axsome Therapeutics
 
Via Benzinga
FedEx To Rally Over 25%? Here Are 10 Other Price Target Changes For Tuesday
Keybanc lowered Salesforce, Inc. (NYSE: CRM) price target from $210 to $200. . Keybanc analyst Michael Turits maintained an Overweight rating on the stock. Salesforce shares gained 0.5% to $154.45 in... 
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $13,000 Today
 
Via Benzinga
Tesla, Apple, Anavex, Axsome, Pinduoduo: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices closed over 1% lower on Monday after protests in China against COVID-zero policies led to supply chain concerns. 
Via Benzinga
Dow Tumbles 450 Points; S&P 500 Falls 1.5%
U.S. stocks traded lower toward the end of trading amid protests over COVID-19 restrictions in China. The Dow Jones dropped more than 450 points on Monday. 
Via Benzinga
10 Things to Know as Tesla Revamps Model 3 With Project ‘Highland’
Recent reports claim that Tesla (TSLA) is planning to revamp the Model 3 under the secret "Highland" project and we have the details! 
Via InvestorPlace
Swvl Layoffs 2022: What to Know About the Latest SWVL Job Cuts
Swvl (SWVL) layoffs are here again as the micro-mobility company seeks to reduce costs by cutting more than 50% of its workforce. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Why Taboola Shares Are Trading Higher By Around 53%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Gainers Taboola.com Ltd. (NASDAQ: TBLA) shares gained 52.5% to $2.8050 after the company announced it entered into a 30-year exclusive commercial agreement with Yahoo. 
Via Benzinga
Why Is Axsome Therapeutics (AXSM) Stock Up 32% Today?
Axsome Therapeutics (AXSM) stock is soaring higher on Monday after releasing positive results from a Phase 3 clinical trial. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Stocks Stumbling After Thanksgiving Week
The Dow Jones Industrial Average is extending its premarket losses, down 265 points at midday, as protests in China over the country's zero-Covid policy weigh on investor sentiment globally. 
Via Talk Markets
Dow Tumbles Over 200 Points; Axsome Therapeutics Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 200 points on Monday. 
Via Benzinga
US Stocks Start Week On Lower Note, Dow Drops Over 100 Points
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Monday. 
Via Benzinga
Axsome Therapeutics Unusual Options Activity
Someone with a lot of money to spend has taken a bullish stance on Axsome Therapeutics (NASDAQ:AXSM). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
Analyst Says Coinbase 'A Waste Of Time', Taylor Swift's Concert Fiasco Under DOJ Probe, Shopify Clocks Record Black Friday Sales: Top Stories Monday, Nov. 28
CNBC 
Via Benzinga
Biogen Dives On Reports Of Alzheimer's Death While Axsome Soars On Its Study Success
Biogen and Axsome stocks diverged Monday on news out of their Alzheimer's studies. 
Via Investor's Business Daily
Why Axsome Therapeutics Stock Is Soaring Today
Axsome Therapeutics Inc (NASDAQ: AXSM) shares are trading higher Monday morning after the company announced AXS-05 achieved its primary endpoint in the ACCORD Phase 3 trial in Alzheimer's disease... 
Via Benzinga
Axsome Therapeutics Investigational Drug Lowers Risk Of Agitation Relapse In Alzheimer's Patients
Axsome Therapeutics Inc's (NASDAQ: AXSM) AXS-05 substantially and statistically significantly delayed the time to relapse and prevented relapse of agitation in patients with Alzheimer's disease,... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Want to Double Your Money? Buying These Stocks Could be a Genius Move
These stocks are undervalued considering their long-term growth potential. 
Via The Motley Fool
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today